A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- Conditions
- Multiple Myeloma
- Interventions
- Registration Number
- NCT03539744
- Lead Sponsor
- AbbVie
- Brief Summary
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 265
- Documented diagnosis of multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria.
- Measurable disease at screening as defined per protocol.
- Has received at least 2 prior lines of therapy as described in the protocol.
- Has had documented disease progression on or within 60 days after completion of the last therapy.
- Has received at least 2 consecutive cycles of lenalidomide and be relapsed/refractory to lenalidomide, as defined per protocol.
- Has received at least 2 consecutive cycles of a proteasome inhibitor (PI).
- Has t(11;14)-positive status determined by an analytically validated fluorescent in situ hybridization (FISH) assay per centralized laboratory testing.
- An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- Laboratory values (liver, kidney and hematology laboratory values) that meet criteria as described per protocol.
- History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or pomalidomide.
- History of other active malignancies, including myelodysplastic syndromes (MDS), within the past 3 years (exceptions described in the protocol).
- Evidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant (SCT).
- Prior treatment with any of the following: allogeneic or syngeneic SCT within 16 weeks prior to randomization; or autologous SCT within 12 weeks prior to randomization.
- Known central nervous system involvement of MM.
- Concurrent conditions as listed in the protocol.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 1 VenDex Dexamethasone Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle. Arm 2 PomDex Dexamethasone Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle. Arm 1 VenDex Venetoclax Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle. Arm 2 PomDex Pomalidomide Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) Up to approximately 43 months from first randomization PFS is defined as the time in days from subject randomization to the date of the first documented progressive disease (PD) or death due to any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Time to Deterioration in Disease Symptoms Up to approximately 51 months from first randomization Time to deterioration in disease symptoms is measured by the disease symptom domain of the European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Module 20 (EORTC QLQ-MY20).
Time to Deterioration in Physical Functioning Up to approximately 51 months from first randomization Time to deterioration in physical functioning is measured by the physical functioning domain of European Organization for Research and Treatment of Cancer Quality of Life Core 30 Question Questionnaire (EORTC-QLQ-C30).
Change from Baseline in PROMIS Fatigue Score Up to approximately 51 months from first randomization Change from baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a score.
Change from Baseline in BPI-SF Worst Pain Score Up to approximately 51 months from first randomization Change from baseline in the Brief Pain Inventory - Short Form (BPI-SF) worst pain score.
Change from Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Up to approximately 51 months from first randomization EQ-5D-5L consists of 2 components: the EQ-5D descriptive system and the EQ visual analog scale (VAS). The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ VAS records the participant's self-rated health on a vertical VAS where the endpoints are labelled "The best health you can imagine" and "The worst health you can imagine."
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Up to approximately 51 months from first randomization EORTC QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Module 20 (EORTC QLQ-MY20) Up to approximately 51 months from first randomization EORTC QLQ-MY20 includes scales for disease symptoms, side effects of treatment, future perspective, and body image. Values for each scale range from 0 to 100.
Duration of response (DOR) Up to approximately 43 months from first randomization DOR for a participant is defined as the number of days from the date of first documented response (PR or better) to the date of first documented PD or death due to multiple myeloma, whichever occurs first.
Overall Response Rate (ORR) Up to approximately 43 months from first randomization ORR is defined as the percentage of participants with documented best response (sCR, CR, VGPR or partial response \[PR\]) prior to first documented PD.
Very Good Partial Response or Better Response Rate (VGPR) Up to approximately 43 months from first randomization VGPR or better response rate is defined as the proportion of participants with documented stringent complete response (sCR), complete response (CR), or VGPR.
Overall survival (OS) Up to approximately 51 months from first randomization OS is defined as the number of days from the date that the participant was randomized to the date of the participant's death.
Minimal Residual Disease (MRD) Negativity Rate Up to approximately 43 months from first randomization MRD defined as the percentage of participants with MRD negativity status. MRD negativity will be defined at 10\^-5 threshold as measured by centralized testing of bone marrow aspirate samples by next generation sequencing (NGS).
Time to Disease Progression (TTP) Up to approximately 43 months from first randomization TTP for a participant is defined as the number of days from the date of randomization to the date of first documented PD or death due to multiple myeloma, whichever occurs first.
Time to Response (TTR) Up to approximately 43 months from first randomization TTR for a participant is defined as the number of days from the date of randomization to the date of first documented response (PR or better).
Cmax of Venetoclax Up to approximately 225 days from initial dose Maximum plasma concentration (Cmax) of venetoclax
Trough Concentration (Ctrough) of Venetoclax Up to approximately 225 days from initial dose Observed plasma concentration at trough (Ctrough) of venetoclax.
Number of Participants With Adverse Events (AEs) Up to approximately 51 months from first randomization An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Trial Locations
- Locations (180)
Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407
🇺🇸Tucson, Arizona, United States
VA Central California Health Care System /ID# 200047
🇺🇸Fresno, California, United States
University of California, Los Angeles /ID# 171524
🇺🇸Los Angeles, California, United States
Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 222904
🇺🇸Aurora, Colorado, United States
Mayo Clinic /ID# 200075
🇺🇸Jacksonville, Florida, United States
Cleveland Clinic Florida /ID# 208884
🇺🇸Weston, Florida, United States
Duplicate_Norton Cancer Institute /ID# 200834
🇺🇸Louisville, Kentucky, United States
University of Maryland, Baltimore /ID# 217422
🇺🇸Baltimore, Maryland, United States
Boston Medical Center /ID# 223606
🇺🇸Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer In /ID# 201377
🇺🇸Detroit, Michigan, United States
Scroll for more (170 remaining)Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407🇺🇸Tucson, Arizona, United States